Found 240 clinical trials
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised …
- 27 views
- 27 Jan, 2021
- 102 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid
- 12 views
- 27 Jan, 2021
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Assessing An Oral Janus Kinase Inhibitor AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20~40 patients will be subsequently …
- 0 views
- 27 Jan, 2021
- 22 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
- 0 views
- 24 Feb, 2021
- 4 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Immunology
-
Currently Recruiting
Study of TG-1701 an Irreversible Bruton's Tyrosine Kinase Inhibitor in Patients With B-Cell Malignancies
This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies
- 117 views
- 13 Feb, 2021
- 15 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Immunology
-
Currently Recruiting
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies
This is a Phase I, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of a novel BTK inhibitor, ICP-022. During this study, dose escalation will be conducted in patients diagnosed with refractory/relapsed (r/r) B-cell malignancies including only patients with Grades1-3a follicular lymphoma (FL); marginal zone lymphoma (MZL); …
- 7 views
- 28 Jan, 2021
- 8 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
The study will include 30 elderly patients age 60-85 with primary CNS DLBCL . Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will …
- 0 views
- 23 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Background Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, …
- 11 views
- 26 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in
- 10 views
- 23 Jan, 2021
- 8 locations
-
Phase 1 trial
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment
- 20 views
- 21 Jan, 2021
- 1 location